| Sensitive periods of substance abuse: Early risk for the transition to dependence CJ Jordan, SL Andersen Developmental cognitive neuroscience 25, 29-44, 2017 | 524 | 2017 |
| Progress in brain cannabinoid CB2 receptor research: From genes to behavior CJ Jordan, ZX Xi Neuroscience & Biobehavioral Reviews 98, 208-220, 2019 | 193 | 2019 |
| Understanding differences in neurotypical and autism spectrum special interests through internet forums CJ Jordan, CL Caldwell-Harris Intellectual and developmental disabilities 50 (5), 391-402, 2012 | 155 | 2012 |
| Evolution of autism support and understanding via the World Wide Web CJ Jordan Intellectual and developmental disabilities 48 (3), 220-227, 2010 | 153 | 2010 |
| Discovery and development of varenicline for smoking cessation CJ Jordan, ZX Xi Expert opinion on drug discovery 13 (7), 671-683, 2018 | 115 | 2018 |
| Systemizing and special interests: Characterizing the continuum from neurotypical to autism spectrum disorder CL Caldwell-Harris, CJ Jordan Learning and Individual Differences 29, 98-105, 2014 | 98 | 2014 |
| Dopamine, behavior, and addiction RA Wise, CJ Jordan Journal of Biomedical Science 28 (1), 83, 2021 | 95 | 2021 |
| Dissecting the role of GABA neurons in the VTA versus SNr in opioid reward E Galaj, X Han, H Shen, CJ Jordan, Y He, B Humburg, GH Bi, ZX Xi Journal of Neuroscience 40 (46), 8853-8869, 2020 | 87 | 2020 |
| Progress in agonist therapy for substance use disorders: Lessons learned from methadone and buprenorphine CJ Jordan, J Cao, AH Newman, ZX Xi Neuropharmacology 158, 107609, 2019 | 76 | 2019 |
| The highly selective dopamine D3R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents CJ Jordan, B Humburg, M Rice, GH Bi, ZB You, AB Shaik, J Cao, ... Neuropharmacology 158, 107597, 2019 | 70 | 2019 |
| CB2 receptor antibody signal specificity: correlations with the use of partial CB2-knockout mice and anti-rat CB2 receptor antibodies H Zhang, H Shen, CJ Jordan, Q Liu, EL Gardner, A Bonci, Z Xi Acta Pharmacologica Sinica 40 (3), 398-409, 2019 | 57 | 2019 |
| Perinatal marijuana use and the developing child LM Jansson, CJ Jordan, ML Velez Jama 320 (6), 545-546, 2018 | 55 | 2018 |
| New drugs, old targets: tweaking the dopamine system to treat psychostimulant use disorders AH Newman, T Ku, CJ Jordan, A Bonifazi, ZX Xi Annual review of pharmacology and toxicology 61 (1), 609-628, 2021 | 54 | 2021 |
| Cannabinoid CB1 receptor neutral antagonist AM4113 inhibits heroin self-administration without depressive side effects in rats X He, CJ Jordan, K Vemuri, G Bi, J Zhan, EL Gardner, A Makriyannis, ... Acta Pharmacologica Sinica 40 (3), 365-373, 2019 | 47 | 2019 |
| mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism X Li, XQ Peng, CJ Jordan, J Li, GH Bi, Y He, HJ Yang, HY Zhang, ... Scientific reports 8 (1), 3686, 2018 | 47 | 2018 |
| Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments CJ Jordan, RC Harvey, BB Baskin, LP Dwoskin, KM Kantak Drug and alcohol dependence 140, 25-32, 2014 | 44 | 2014 |
| Adolescent atomoxetine treatment in a rodent model of ADHD: effects on cocaine self-administration and dopamine transporters in frontostriatal regions SS Somkuwar, CJ Jordan, KM Kantak, LP Dwoskin Neuropsychopharmacology 38 (13), 2588-2597, 2013 | 44 | 2013 |
| Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders AH Newman, J Cao, JD Keighron, CJ Jordan, GH Bi, Y Liang, ... Neuropsychopharmacology 44 (8), 1435-1444, 2019 | 41 | 2019 |
| Reconceptualizing non-pharmacologic approaches to Neonatal Abstinence Syndrome (NAS) and Neonatal Opioid Withdrawal Syndrome (NOWS): A theoretical and evidence–based approach … ML Velez, C Jordan, LM Jansson Neurotoxicology and Teratology 88, 107032, 2021 | 39 | 2021 |
| Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments RC Harvey, CJ Jordan, DH Tassin, KR Moody, LP Dwoskin, KM Kantak Behavioural brain research 244, 38-47, 2013 | 38 | 2013 |
